RhumbLine Advisers’s Avidity Biosciences RNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.98M | Buy |
175,359
+10,583
| +6% | +$301K | ﹤0.01% | 1414 |
|
|
2025
Q1 | $4.86M | Buy |
164,776
+10,973
| +7% | +$324K | ﹤0.01% | 1373 |
|
|
2024
Q4 | $4.47M | Buy |
153,803
+4,795
| +3% | +$139K | ﹤0.01% | 1476 |
|
|
2024
Q3 | $6.84M | Buy |
149,008
+7,527
| +5% | +$346K | 0.01% | 1252 |
|
|
2024
Q2 | $5.78M | Buy |
141,481
+22,604
| +19% | +$923K | 0.01% | 1309 |
|
|
2024
Q1 | $3.03M | Buy |
118,877
+4,110
| +4% | +$105K | ﹤0.01% | 1685 |
|
|
2023
Q4 | $1.04M | Buy |
114,767
+4,330
| +4% | +$39.2K | ﹤0.01% | 2228 |
|
|
2023
Q3 | $705K | Sell |
110,437
-485
| -0.4% | -$3.09K | ﹤0.01% | 2401 |
|
|
2023
Q2 | $1.23M | Buy |
110,922
+13,825
| +14% | +$153K | ﹤0.01% | 2180 |
|
|
2023
Q1 | $1.49M | Buy |
97,097
+16,645
| +21% | +$255K | ﹤0.01% | 1961 |
|
|
2022
Q4 | $1.79M | Buy |
80,452
+3,197
| +4% | +$70.9K | ﹤0.01% | 1842 |
|
|
2022
Q3 | $1.26M | Buy |
77,255
+7,876
| +11% | +$129K | ﹤0.01% | 2019 |
|
|
2022
Q2 | $1.01M | Buy |
69,379
+23,249
| +50% | +$338K | ﹤0.01% | 2142 |
|
|
2022
Q1 | $852K | Buy |
46,130
+1,932
| +4% | +$35.7K | ﹤0.01% | 2196 |
|
|
2021
Q4 | $1.05M | Buy |
44,198
+1,574
| +4% | +$37.4K | ﹤0.01% | 2182 |
|
|
2021
Q3 | $1.05M | Buy |
42,624
+5,113
| +14% | +$126K | ﹤0.01% | 2209 |
|
|
2021
Q2 | $927K | Buy |
37,511
+6,985
| +23% | +$173K | ﹤0.01% | 2278 |
|
|
2021
Q1 | $666K | Buy |
30,526
+11,214
| +58% | +$245K | ﹤0.01% | 2361 |
|
|
2020
Q4 | $493K | Buy |
19,312
+1,796
| +10% | +$45.8K | ﹤0.01% | 2446 |
|
|
2020
Q3 | $493K | Buy |
+17,516
| New | +$493K | ﹤0.01% | 2297 |
|